| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Tuesday’s Close |
|---|---|---|---|---|---|
| BIOS | BioScrip, Inc. | $2.99 | $382.86M | Sell |
Daré Bio up 154% on positive tamoxifen data
https://seekingalpha.com/news/3443719-dare-bio-154-percent-positive-tamoxifen-data?source=feed_news_all
Mar 18, 2019 - Thinly traded nano cap Daré Bioscience (DARE +154.3%) is up on a 525x explosion in volume in response to positive clinical data supporting the value proposition of its vaginally administered tamoxifen
0
BTIG likes Arcus Bio in premarket analyst action
https://seekingalpha.com/news/3443584-btig-likes-arcus-bio-premarket-analyst-action?source=feed_news_all
Mar 18, 2019 - Momenta Pharmaceuticals (NASDAQ:MNTA) initiated with Neutral rating at BTIG Research.Arcus Biosciences (NYSE:RCUS) initiated with Buy rating and $20 (71% upside) price target at BTIG.Exelixis (NASDAQ:
0
Mustang Bio reports FY results
https://seekingalpha.com/news/3443543-mustang-bio-reports-fy-results?source=feed_news_all
Mar 18, 2019 - Mustang Bio (NASDAQ:MBIO): FY GAAP EPS of -$1.14.Cash and cash equivalents of $16.5MPress Release
0
Bioscrip Inc (BIOS) Q4 2018 Earnings Conference Call Transcript
https://www.fool.com/earnings/call-transcripts/2019/03/15/bioscrip-inc-bios-q4-2018-earnings-conference-call.aspx?source=iedfolrf0000001
Mar 15, 2019 - BIOS earnings call for the period ending December 31, 2018.
0
BioScrip, Inc. (BIOS) CEO Dan Greenleaf on Q4 2018 Results, and BioScrip and Option Care Merger Transaction (Transcript)
https://seekingalpha.com/article/4249145-bioscrip-inc-bios-ceo-dan-greenleaf-q4-2018-results-bioscrip-option-care-merger-transaction?source=feed_sector_transcripts
Mar 15, 2019 - BioScrip, Inc. (NASDAQ:BIOS) Q4 2018 Results and BioScrip, and Option Care Merger Transaction Conference Call March 15, 2019 09:00 AM ET Company Participants Kathryn Stalmack - SVP and General Counsel
0
Achieve Life Sciences and Karyopharm Therapeutics among healthcare gainers; Biocept and BioScrip among losers
https://seekingalpha.com/news/3443283-achieve-life-sciences-karyopharm-therapeutics-among-healthcare-gainers-biocept-bioscrip-among?source=feed_news_all
Mar 15, 2019 - Gainers: Soleno Therapeutics (NASDAQ:SLNO) +249%. Achieve Life Sciences (NASDAQ:ACHV) +42%. Catasys (NASDAQ:CATS) +23%. Karyopharm Therapeutics (NASDAQ:KPTI) +23%. PhaseBio Pharmaceuticals (NASDAQ:PHA
0
BioScrip, Inc. 2018 Q4 - Results - Earnings Call Slides
https://seekingalpha.com/article/4249062-bioscrip-inc-2018-q4-results-earnings-call-slides?source=feed_all_articles
Mar 15, 2019 - The following slide deck was published by BioScrip, Inc. in conjunction with their 2018 Q4 earnings call.
0
Marrone Bio Reports Q4 Earnings, Plans To Prioritize Cannabis Market
http://feeds.benzinga.com/~r/benzinga/~3/1bBRbQCp3gM/marrone-bio-reports-q4-earnings-plans-to-prioritize-cannabis-market
Mar 15, 2019 -
Crop protection and plant health solutions company Marrone Bio Innovations Inc (NASDAQ: MBII) reported financial results for the fourth quarter and full year Thursday.
The Davis, California-based company posted fourth-quarter revenue of $5.7 million, up by 72 percent on the year.
0
Hemispherx Bio up 8% on Ampligen progress
https://seekingalpha.com/news/3442310-hemispherx-bio-8-percent-ampligen-progress?source=feed_news_all
Mar 13, 2019 - Nano cap Hemispherx Biopharma (HEB +7.5%) is up on more than triple normal volume following its update on its Ampligen programs. It plans to release additional updates on a quarterly basis.Multiple cl
0
Moleculin Bio up 8% premarket on potential accelerated review for Annamycin
https://seekingalpha.com/news/3442262-moleculin-bio-8-percent-premarket-potential-accelerated-review-annamycin?source=feed_news_all
Mar 13, 2019 - Thinly traded nano cap Moleculin Biotech (NASDAQ:MBRX) is up 8% premarket on average volume on the heels of its request for Fast Track status from the FDA related to Annamycin for relapsed/refractory
0
Page 1>
Related Companies
| Name | Exchange | Price | Mkt Cap | |
| CIVI | Civitas Solutions, Inc. | NYSE | $14.35 | $519.89M |
| CCM | Concord Medical Services Holdings Limited | NYSE | $3.499 | $151.73M |
| PETS | PetMed Express, Inc. | NASDAQ | $36.88 | $762.88M |
| ADUS | Addus HomeCare Corporation | NASDAQ | $68.95 | $806.53M |
| KANG | iKang Healthcare Group, Inc. | NASDAQ | $17.41 | $1.21B |
BIOS - Nasdaq
http://www.nasdaq.com/symbol/bios
Quote information directly from the exchange
SEC filings
Comparison
Ownership
Insiders
Institutions
Revenue/EPS
Competitors
Guru
Report
Analysts
Pre-market
Quote
Consultant
After hours
Transcripts
BIOS - Google Finance
https://www.google.com/finance?q=BIOS
Industry related info and international coverage
Summary
News
BIOS - Bloomberg
http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=BIOS
Original news and commentary from Bloomberg
Charts
Financials with pensions
Snapshot
Earnings
Transactions
People
Options